Latent tuberculosis infection: a new paradigm

M. Behr (Montréal, Canada)

Source: International Congress 2019 – State of the art session: Respiratory infections
Session: State of the art session: Respiratory infections
Session type: Symposium
Number: 1540
Disease area: Respiratory infections

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Behr (Montréal, Canada). Latent tuberculosis infection: a new paradigm. International Congress 2019 – State of the art session: Respiratory infections

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment of latent infection with Mycobacterium tuberculosis: update 2010
Source: Eur Respir J 2011; 37: 690-711
Year: 2011



Latent tuberculosis: diagnostic and treatment
Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment
Year: 2008


Latent tuberculosis infection in a drug treatment centre
Source: Eur Respir J 2002; 20: Suppl. 38, 366s
Year: 2002

Can we define latent tuberculosis infection?
Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches
Year: 2003

How should we treat latent tuberculosis infection?
Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches
Year: 2003

Latent tuberculosis infection as a cause of tuberculosis disease
Source: Eur Respir J 2003; 22: Suppl. 45, 157s
Year: 2003

Diagnosis of latent tuberculosis infection
Source: ERS Live 2007
Year: 2007

What is latent tuberculosis infection (LTBI)?
Source: Annual Congress 2009 - Microbial colonisation or latency: a foot in the door to respiratory infections
Year: 2009


Screening migrants for tuberculosis and latent TB infection: the reward will come later
Source: Eur Respir J, 54 (4) 1901719; 10.1183/13993003.01719-2019
Year: 2019



Multiple cytokine response to mycobacterium tuberculosis with a whole blood assay is useful to distinguish active from latent tuberculosis infection in a highly tuberculosis endemic country
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 2
Year: 2014


Direct costs of three models for the screening of latent tuberculosis infection
Source: Eur Respir J 2006; 28: 45-50
Year: 2006



Latent tuberculosis in the nonimmunocompromised host
Source: Annual Congress 2006 - PG11 - Clinical highlights on tuberculosis
Year: 2006

Persistent M. tuberculosis infection: experimental model of endogenously re-activated TB
Source: Eur Respir J 2002; 20: Suppl. 38, 582s
Year: 2002

Diagnosis and treatment of latent tuberculosis infection
Source: Eur Respir Monogr 2018; 82: 381-398
Year: 2018


Different genetics background of patients with latent tuberculosis infection versus active tuberculosis
Source: International Congress 2017 – Asthma genetics and genomics in patients and populations
Year: 2017


Latent tuberculosis assessment before biological agent use
Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection
Year: 2020

Cost-effectiveness of two latent tuberculosis infection screening strategies
Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity
Year: 2018




Latent tuberculosis
Source: Respipedia Article
Year: 2018

Treatment failure in tuberculosis
Source: Eur Respir J 2007; 29: 561-564
Year: 2007